Abstract
Prospective observational studies have shown that arterial stiffness is a strong and independent predictor of cardiovascular disease in hemodialysis patients. Recent evidence further supports that arterial hardening predicts cardiovascular and all-cause mortality in peritoneal dialysis patients, renal transplant recipients and patients with chronic kidney disease (CKD) not on dialysis. Of note, dissociation of arterial stiffness with blood pressure reduction were related to worsened cardiovascular outcome in kidney disease patients, suggesting that arterial stiffness may not only be a predictor, but also a true risk factor, representing a specific and potentially reversible pattern of outward arterial remodeling in these individuals. On this basis, arterial stiffness has emerged as a novel therapeutic target for cardiovascular risk reduction in patients with CKD; specific interventions, such as renin-angiotensin-system blockade, use of statins, and decrease of calcium- phosphate product may delay the progression of arteriosclerotic process. This article summarizes the accumulated evidence from clinical and epidemiological studies regarding the prognostic significance of arterial stiffening on cardiovascular outcomes and provides insights on possible treatment strategies for arterial stiffness attenuation in patients with CKD.
Keywords: Arterial stiffness, arterial remodeling, chronic kidney disease, end-stage renal disease, cardiovascular morbidity, cardiovascular mortality.
Current Vascular Pharmacology
Title:Arterial Stiffness: A Novel Cardiovascular Risk Factor in Kidney Disease Patients
Volume: 13 Issue: 2
Author(s): Panagiotis I. Georgianos, Pantelis A. Sarafidis and Anastasios N. Lasaridis
Affiliation:
Keywords: Arterial stiffness, arterial remodeling, chronic kidney disease, end-stage renal disease, cardiovascular morbidity, cardiovascular mortality.
Abstract: Prospective observational studies have shown that arterial stiffness is a strong and independent predictor of cardiovascular disease in hemodialysis patients. Recent evidence further supports that arterial hardening predicts cardiovascular and all-cause mortality in peritoneal dialysis patients, renal transplant recipients and patients with chronic kidney disease (CKD) not on dialysis. Of note, dissociation of arterial stiffness with blood pressure reduction were related to worsened cardiovascular outcome in kidney disease patients, suggesting that arterial stiffness may not only be a predictor, but also a true risk factor, representing a specific and potentially reversible pattern of outward arterial remodeling in these individuals. On this basis, arterial stiffness has emerged as a novel therapeutic target for cardiovascular risk reduction in patients with CKD; specific interventions, such as renin-angiotensin-system blockade, use of statins, and decrease of calcium- phosphate product may delay the progression of arteriosclerotic process. This article summarizes the accumulated evidence from clinical and epidemiological studies regarding the prognostic significance of arterial stiffening on cardiovascular outcomes and provides insights on possible treatment strategies for arterial stiffness attenuation in patients with CKD.
Export Options
About this article
Cite this article as:
Georgianos I. Panagiotis, Sarafidis A. Pantelis and Lasaridis N. Anastasios, Arterial Stiffness: A Novel Cardiovascular Risk Factor in Kidney Disease Patients, Current Vascular Pharmacology 2015; 13 (2) . https://dx.doi.org/10.2174/15701611113119990147
DOI https://dx.doi.org/10.2174/15701611113119990147 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Sex Differences in Clinical Outcomes of Patients with Stable Coronary Artery Disease after Percutaneous Coronary Intervention
Current Pharmaceutical Design Molecular Targets and Natural Compounds in Drug Development for the Treatment of Inflammatory Pain
Current Drug Targets Pros and Cons of Aggressive Blood Pressure Lowering in Patients with Type 2 Diabetes
Current Vascular Pharmacology The Role of Apelins in the Physiology of the Heart
Protein & Peptide Letters Future Perspectives in the Pharmacological Treatment of Atrial Fibrillation and Ventricular Arrhythmias in Heart Failure
Current Pharmaceutical Design Alzheimers Disease Burdens African-Americans: A Review of Epidemiological Risk Factors and Implications for Prevention and Treatment
Current Psychiatry Reviews Editorial (Thematic Issue: Antiplatelet Treatment in Cardiovascular Disease: New Insights)
Current Pharmaceutical Design Sleep-Disordered Breathing and Cardiovascular Disease: Exploring Pathophysiology and Existing Data
Current Respiratory Medicine Reviews MicroRNAs in the Diagnosis and Treatment of Unstable Angina
Current Topics in Medicinal Chemistry Nanobiotechnological Approaches Against Multidrug Resistant Bacterial Pathogens: An Update
Current Drug Metabolism Weka Machine Learning for Predicting the Phospholipidosis Inducing Potential
Current Topics in Medicinal Chemistry Recent Medicinal Chemistry Studies for Multitarget Agents-Part II
Current Drug Targets Microarray Profiling Analysis Uncovers Common Molecular Mechanisms of Rubella Virus, Human Cytomegalovirus, and Herpes Simplex Virus Type 2 Infections in ECV304 Cells
Current Molecular Medicine The Role of Uric Acid and Methyl Derivatives in the Prevention of Age-Related Neurodegenerative Disorders
Current Topics in Medicinal Chemistry Risk Factors for Ischemic Heart Disease
Reviews on Recent Clinical Trials Editorial [ Cardiovascular Risk Factor Modification: A sine qua non in the Management of Vascular Surgery Patients ]
Current Vascular Pharmacology Pharmacogenetics of HMG-CoA Reductase Inhibitors: Optimizing the Prevention of Coronary Heart Disease
Current Pharmacogenomics and Personalized Medicine Antisense DNA and RNA: Potential Therapeutics for Viral Infection
Anti-Infective Agents in Medicinal Chemistry Current Research Issues in the Pharmacokinetics of Antiretroviral Drugs in Children
Current Pediatric Reviews Discovering Natural Product Modulators to Overcome Multidrug Resistance in Cancer Chemotherapy
Current Pharmaceutical Biotechnology